NKTX

Healthcare Biotechnology

Nkarta, Inc.

$2.35

-0.21 -8.40% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 6, 2026, live at 2:54 PM ET	2.35

Key Stats

Market Cap

167.96M

Avg Volume

638,081

EPS

-$1.58

52W High

$3.72

52W Low

$1.70

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-1.34

P/B Ratio

0.68

EV/EBITDA

-0.64

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(38.8%)

Return on Assets

(19.6%)

Liquidity & Leverage

Current Ratio

7.98

Quick Ratio

7.85

Debt / Equity

0.30

Total Cash

182.76M

Total Debt

73.54M

About

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.